Sameer S Kadri, MD, MS

Critical Care Medicine, National Institutes of Health Clinical Center
Bethesda, Maryland, United States

I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presentation(s):

• 1649 - Ceftolozane-Tazobactam or Ceftazidime-Avibactam Versus Best Available Therapy in the Treatment of Difficult-to-Treat Pseudomonas aeruginosa Infections: a Retrospective Comparative Effectiveness Analysis of 195 U.S. Hospitals, 2016–2020

  Saturday, October 22, 2022
  10:30 AM – 10:45 AM US ET